敲低心肌连接斑株蛋白对人胃癌SGC-7901细胞的迁移和侵袭能力的影响及机制研究

该文研究了敲低心肌连接斑株蛋白(junction plakoglobin,JUP)对人胃癌SGC-7901细胞迁移和侵袭的影响及其机制。通过sh RNA慢病毒介导的方式构建了敲低JUP基因的慢病毒载体序列及其阴性对照病毒,并感染至人胃癌SGC-7901细胞中,荧光检测细胞感染效率,获得JUP基因稳定沉默及其对照细胞株。用嘌呤霉素筛选阳性转染细胞株,采用实时荧光定量PCR(q RT-PCR)和蛋白质免疫印记法(Western blot)检测JUP表达水平。采用细胞划痕愈合实验和Transwell小室实验检测敲低JUP基因之后对人胃癌SGC-7901细胞迁移和侵袭能力的影响。采用Western blot检测敲低JUP之后β-连环蛋白水平的影响。结果显示,通过sh RNA介导的慢病毒成功构建了敲低JUP基因的人胃癌SGC-7901稳定细胞株。与对照组相比,敲低JUP表达可促进细胞的迁移和侵袭能力(P0.05),上调了β-连环蛋白的水平(P0.05)。以上结果表明,敲低人胃癌SGC-7901细胞中JUP基因表达后可促进胃癌细胞SGC-7901的迁移和侵袭能力可能与其上调β-连环蛋白的水平从而活化Wnt信号通路有关。     

沉默MDR1基因增强SGC7901/ADM细胞对姜黄素的敏感性

本研究利用短发夹RNA(sh RNA)沉默SGC7901/ADM细胞MDR1基因表达,增强人胃癌SGC7901/ADM细胞对姜黄素的敏感性。根据MDR1基因序列设计3对编码sh RNA的DNA模板,克隆到p Silencer 3.1-H1 neo(p3.1)上构建3种sh RNA表达载体,转染SGC7901/ADM细胞,q RT-PCR和Western blotting检测MDR1基因沉默效果,用荧光显微镜观察细胞形态,MTT法检测细胞活力。结果显示,3种sh RNA表达载体转染细胞后均能不同程度沉默MDR1基因的表达,增强了细胞对姜黄素的敏感性。     

Snai1 miRNA干扰质粒构建及胃癌细胞系稳定株筛选

目的：设计并构建针对Snai1的微小干扰核糖核酸（miRNA）,最终鉴定出有效干扰质粒并筛选稳定转染的胃癌细胞株SGC-7901。方法：设计并构建4对Snai1的pcDNATM6.2-GW/EmGFPmiR microRNA及1对无效对照microRNA干扰质粒。将干扰质粒用罗氏BD转染试剂转染胃癌细胞株SGC-7901,通过倒置荧光显微镜观察绿色荧光确定转染效率。分别用不同浓度l的杀稻瘟菌素作用于SGC-7901细胞,得到杀稻瘟菌素对SGC-7901细胞的筛选浓度。Westernblot检测4对干扰质粒、阴性对照质粒对snai1蛋白水平表达的影响。结果：测序表明,Snai1干扰序列及读码框完全正确,干扰质粒瞬时转染的SGC-7901细胞系在倒置荧光显微镜下观察绿色荧光达85%以上。杀稻瘟菌素对于SGC-7901细胞的筛选浓度为5μg/ml。Westernblot结果显示,干扰序列Mi-1对Snai1有较强的干扰效果。结论：成功构建了Snai1干扰真核表达载体,同时筛选出有效干扰质粒及稳定转染株,为进一步研究Snai1在胃癌中的作用奠定了基础。     

NK细胞中过表达Livin的实验研究

目的:将携带Livin的质粒pIRES2-EGFP-Livin进行扩增,转染自然杀伤细胞(NK)及胃癌细胞株SGC-7901,并检测其在NK及胃癌细胞株SGC-7901中的表达。方法:将携带Livin基因的质粒p IRES2-EGFP-Livin进行扩增,鉴定质粒纯度与浓度;从健康人外周血中获得NK细胞,应用HP转染试剂将质粒pIRES2-EGFP-Livin转染体外培养的NK及胃癌细胞,对比分析NK及胃癌细胞株SGC-7901中基因转染效率及目的基因的表达情况。结果:用无血清培养基在体外成功的扩增大量的NK细胞;质粒提取试剂盒抽提得到大量无内毒素的质粒,质粒DNA基因序列并未发生突变,浓度和纯度较高。胃癌细胞株SGC-7901中观察到明显的质粒pIRES2-EGFP-Livin绿色荧光表达;而NK中未观察到绿色荧光表达。结论:质粒pIRES2-EGFP-Livin能使Lvin蛋白表达于胃癌细胞株SGC-7901中,而在NK中未表达。     

Snai1 miRNA干扰质粒构建及胃癌细胞系稳定株筛选

目的:设计并构建针对Snai1的微小干扰核糖核酸(miRNA),最终鉴定出有效干扰质粒并筛选稳定转染的胃癌细胞株SGC-7901。方法:设计并构建4对Snai1的pcDNATM6.2-GW/EmGFPmiR microRNA及1对无效对照microRNA干扰质粒。将干扰质粒用罗氏BD转染试剂转染胃癌细胞株SGC-7901,通过倒置荧光显微镜观察绿色荧光确定转染效率。分别用不同浓度l的杀稻瘟菌素作用于SGC-7901细胞,得到杀稻瘟菌素对SGC-7901细胞的筛选浓度。Westernblot检测4对干扰质粒、阴性对照质粒对snai1蛋白水平表达的影响。结果:测序表明,Snai1干扰序列及读码框完全正确,干扰质粒瞬时转染的SGC-7901细胞系在倒置荧光显微镜下观察绿色荧光达85%以上。杀稻瘟菌素对于SGC-7901细胞的筛选浓度为5μg/ml。Westernblot结果显示,干扰序列Mi-1对Snai1有较强的干扰效果。结论:成功构建了Snai1干扰真核表达载体,同时筛选出有效干扰质粒及稳定转染株,为进一步研究Snai1在胃癌中的作用奠定了基础。     

下调lincRNA HOTAIR对胃癌细胞迁移及增殖抑制作用的研究

通过下调人胃癌细胞BGC823中linc RNA HOTAIR基因的表达,该文探讨了linc RNA HOTAIR低表达对胃癌细胞迁移、侵袭及增殖能力的影响。该文构建针对人linc RNA HOTAIR基因的干扰质粒sh HOTAIR,稳定转染入胃癌细胞BGC823、筛选稳转株,q PCR检测linc RNA HOTAIR在胃癌细胞中表达水平。采用划痕试验、侵袭试验、MTT法分别检测转染胃癌细胞迁移、侵袭及增殖能力。结果表明,稳定转染干扰质粒sh HOTAIR后下调linc RNA HOTAIR表达的胃癌细胞株细胞迁移、侵袭及增殖能力较阴性对照组明显减弱。下调胃癌细胞中linc RNA HOTAIR的表达,可降低胃癌细胞的迁移力、侵袭性、抑制其增殖能力,提示linc RNA HOTAIR可作为分子靶点用于胃癌的分子靶向治疗。     

白黎芦醇对胃癌SGC 一7 901 细胞V EGF 表达的影响

目的：探讨白藜芦醇（resveratrol,Res）在体外对胃癌SGC-7901细胞VEGF表达的影响。方法：体外培养胃癌SGC-7901细胞,MTT法检测白藜芦醇对SGC-7901细胞的增殖抑制作用,RT—PCR方法检测VEGFmRNA表达,免疫细胞化学检测VEGF蛋白的表达。结果：白藜芦醇呈时间剂量性抑制胃癌细胞SGC7901的增殖;胃癌SGC-7901细胞高水平表达VEGF,白藜芦醇能显著降低胃癌SGC-7901细胞VEGFmRNA和蛋白表达。结论：白藜芦醇可以下调胃癌SGC-7901细胞VEGF的表达,抑制胃癌细胞的增殖。     

迁移侵袭抑制蛋白抑制胃癌细胞增殖迁移及侵袭

目的检测迁移侵袭抑制蛋白(migration and invasion inhibi tory protein,MIIP)基因在胃癌中的表达情况及其在胃癌发生发展过程中起到的作用,为探究胃癌发生的分子机制和靶向治疗提供实验依据。方法 Western blot和免疫组织化学法检测MIIP在胃癌组织的表达。胃癌SGC7901细胞中转染MIIP过表达质粒及其空质粒,应用细胞功能学实验检测MIIP过表达对胃癌细胞增殖、迁移和侵袭能力的影响。结果 MIIP在胃癌组织标本中的表达低于癌旁正常胃粘膜;细胞功能实验结果显示,MIIP过表达可抑制胃癌细胞的增殖、迁移和侵袭能力。结论过表达MIIP可以抑制胃癌SGC7901细胞增殖、迁移和侵袭的能力。     

慢病毒siRNA靶向干扰YAP基因胃癌细胞株的建立

目的:构建并鉴定YAP基因短发夹干扰RNA(shRNA)慢病毒载体,建立稳定干扰YAP基因表达的胃癌细胞株SGC7901。方法:荧光定量PCR检测YAP基因在多种胃癌细胞株中的表达情况。构建重组靶向YAP基因的shRNA慢病毒表达质粒PGC-shRNA-YAP,用脂质体转染的方法将载体导入胃癌细胞。经杀稻瘟菌素筛选后,建立稳定表达siRNA的细胞株。荧光定量PCR检测干扰效率。结果:在胃癌细胞株SGC7901中,YAP基因显示高表达。测序验证PGC-shRNA-YAP重组质粒构建成功。将重组质粒稳定转染入胃癌细胞株SGC7901后能明显抑制YAPmRNA表达水平。结论:成功构建了PGC-shRNA-YAP慢病毒重组质粒,建立了靶向稳定干扰YAP基因表达的siRNA胃癌细胞株SGC7901。     

慢病毒siRNA靶向干扰YAP基因胃癌细胞株的建立

目的：构建并鉴定YAP基因短发夹干扰RNA（shRNA）慢病毒载体,建立稳定干扰YAP基因表达的胃癌细胞株SGC7901。方法：荧光定量PCR检测YAP基因在多种胃癌细胞株中的表达情况。构建重组靶向YAP基因的shRNA慢病毒表达质粒PGC-shRNA-YAP,用脂质体转染的方法将载体导入胃癌细胞。经杀稻瘟菌素筛选后,建立稳定表达siRNA的细胞株。荧光定量PCR检测干扰效率。结果：在胃癌细胞株SGC7901中,YAP基因显示高表达。测序验证PGC-shRNA-YAP重组质粒构建成功。将重组质粒稳定转染入胃癌细胞株SGC7901后能明显抑制YAPmRNA表达水平。结论：成功构建了PGC-shRNA-YAP慢病毒重组质粒,建立了靶向稳定干扰YAP基因表达的siRNA胃癌细胞株SGC7901。     

细胞色素P450 1A1和1B1靶向抗肿瘤前药研究进展

细胞色素P450（CYP）能催化各种内源性及外源性化合物的代谢,与多种肿瘤发生有关。其中CYP1A1参与多种前致癌物和致突变物的代谢活化,CYP1B1被认为在许多人癌细胞中特异性表达,参与药物的氧化代谢和前药的活化。CYP1A1和181已成为靶向抗肿瘤前药研究的新靶点。相继有大量相关研究报道,本文就近年来文献报道的CYP1A1和1B1靶向抗肿瘤前药研究进展。     

Liver kinase B1 regulates the centrosome via PLK1

Liver kinase B1 (LKB1) is a tumor suppressor mutationally inactivated in Peutz–Jeghers syndrome (PJS) and various sporadic cancers. Although LKB1 encodes a kinase that possesses multiple functions, no individual hypothesis posed to date has convincingly explained how loss of LKB1 contributes to carcinogenesis. In this report we demonstrated that LKB1 maintains genomic stability through the regulation of centrosome duplication. We found that LKB1 colocalized with centrosomal proteins and was situated in the mitotic spindle pole. LKB1 deficiency-induced centrosome amplification was independent of AMP-activated protein kinase (AMPK), a well-defined substrate of LKB1. Cells lacking LKB1 exhibited an increase in phosphorylated and total Polo-like kinase 1 (PLK-1), NIMA-related kinase 2 (NEK2), and ninein-like protein (NLP). Overexpression of active PLK1 (T210D) reversed the inhibition of LKB1 on centrosome amplification. In contrast, depletion of PLK1 with siRNA or suppression of PLK1 kinase activity with BTO-1 (5-Cyano-7-nitro-2-benzothiazolecarboxamide-3-oxide) abrogated LKB1 deficiency-induced centrosome amplification. We further characterized that LKB1 phosphorylated and activated AMPK-related kinase 5 (NUAK1 or ARK5) that in turn increased the phosphorylation of MYPT1, enhanced the binding between MYPT1–PP1 and PLK1, and conferred an effective dephosphorylation of PLK1. More importantly, we noted that LKB1-deficient cells exhibited multiple nuclear abnormalities, such as mitotic delay, binuclear, polylobed, grape, large, and micronuclear. Immediate depletion of LKB1 resulted in the accumulation of multiploidy cells. Expression of LKB1 is reversely correlated with the levels of PLK1 in human cancer tissues. Thus, we have uncovered a novel function of LKB1 in the maintenance of genomic stability through the regulation of centrosome mediated by PLK1.     

NP c 1L l 在高脂血症和动脉粥样硬化中的表达分析

目的：研究NPC1L1（Niemann-Pick C1 Like 1）mRNA在单纯高脂血症大鼠和动脉粥样硬化大鼠小肠组织中的表达与差异,探讨其与脂质代谢和动脉粥样硬化之间的关系。方法：通过半定量RT-PCR方法分别检测正常普食组、单纯高脂饲养组和动脉粥样大鼠组小肠组织中NPC1L1 mRNA的表达差异。结果：三个组别大鼠小肠组织中均存在NPC1L2 mRNA,单纯高脂饮食和动脉粥样大鼠小肠组织中NPC1L1 mRNA表达明显高于正常对照大鼠（P〈0．01）;单纯高脂饮食和动脉粥样大鼠小肠组织中NPC1L1 mRNA表达之间无明显差异（P〉0．05）。结论：血脂代谢紊乱与小肠组织中NPC1L1的高表达有关,NPC1L1可能参与了血脂紊乱的病理生理过程;NPC1L1与促成动脉粥样硬化的发生无明显相关性。     

Structural insights into the negative regulation of BRI1 signaling by BRI1-interacting protein BKI1

Brassinosteroids (BRs) are essential steroid hormones that have crucial roles in plant growth and development. BRs are perceived by the cell-surface receptor-like kinase brassinosteroid insensitive 1 (BRI1). In the absence of BRs, the cytosolic kinase domain (KD) of BRI1 is inhibited by its auto-inhibitory carboxyl terminus, as well as by interacting with an inhibitor protein, BRI1 kinase inhibitor 1 (BKI1). How BR binding to the extracellular domain of BRI1 leads to activation of the KD and dissociation of BKI1 into the cytosol remains unclear. Here we report the crystal structure of BRI1 KD in complex with the interacting peptide derived from BKI1. We also provide biochemical evidence that BRI1-associated kinase 1 (BAK1) plays an essential role in initiating BR signaling. Steroid-dependent heterodimerization of BRI1 and BAK1 ectodomains brings their cytoplasmic KDs in the right orientation for competing with BKI1 and transphosphorylation.     

Roles for N-glycosylation in the dynamics of Edg-1/S1P1 in sphingosine 1-phosphate-stimulated cells

Sphingosine 1-phosphate (Sph-1-P) is a bioactive lipid mediator released from activated platelets. To date, 5 seven-transmembrane-spanning receptors, Edg-1/S1P1, Edg-3/S1P3, Edg-5/S1P2, Edg-6/S1P4 and Edg-8/S1P5, have been identified as specific Sph-1-P receptors. Our recent novel studies established that Edg-1/S1P1 is glycosylated in its N-terminal extracellular portion and further identified the specific glycosylation site as asparagine 30. We also demonstrated that the structure of the N-terminal ectodomain of Edg-1/S1P1 affects both its transport to the cell surface and the N-glycosylation process. These studies revealed a possible regulatory role for the N-glycan on Edg-1/S1P1 in the dynamics of the receptor, such as its lateral and internal movements within the membrane, in ligand-stimulated mammalian cells. Published in 2004.